Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations: 2016-2024

Historic Cash from Operations for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$226.0 million.

  • Crinetics Pharmaceuticals' Cash from Operations fell 76.24% to -$110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$347.7 million, marking a year-over-year decrease of 72.25%. This contributed to the annual value of -$226.0 million for FY2024, which is 35.88% down from last year.
  • Crinetics Pharmaceuticals' Cash from Operations amounted to -$226.0 million in FY2024, which was down 35.88% from -$166.3 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Operations peaked at -$62.0 million during FY2020, and registered a low of -$226.0 million during FY2024.
  • In the last 3 years, Crinetics Pharmaceuticals' Cash from Operations had a median value of -$166.3 million in 2023 and averaged -$169.2 million.
  • Data for Crinetics Pharmaceuticals' Cash from Operations shows a maximum YoY tumbled of 44.36% (in 2023) over the last 5 years.
  • Crinetics Pharmaceuticals' Cash from Operations (Yearly) stood at -$62.0 million in 2020, then plummeted by 42.82% to -$88.6 million in 2021, then slumped by 30.05% to -$115.2 million in 2022, then slumped by 44.36% to -$166.3 million in 2023, then tumbled by 35.88% to -$226.0 million in 2024.